Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch aimed at restoring light perception in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Another key product, KIO-101, is a next-generation, non-steroidal, immuno-modulatory small molecule designed to inhibit dihydroorotate dehydrogenase (DHODH) with the goal of minimizing side effects typically associated with DHODH inhibitors. Additionally, Kiora is advancing KIO-201, a modified form of hyaluronic acid intended to enhance corneal wound healing. Through these developments, Kiora aims to address unmet medical needs in the field of ophthalmology.